UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant **x**

Filed by a Party other than the Registrant \Box

Check the appropriate box:	
	Preliminary Proxy Statement
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
	Definitive Proxy Statement
х	Definitive Additional Materials
	Soliciting Material under §240.14a-12

HAEMONETICS[®]

HAEMONETICS CORPORATION

(Name of Registrant as Specified in Its Charter)

Payment of Filing Fee (Check the appropriate box):	
х	No fee required.
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	(1) Title of each class of securities to which transaction applies:
	(2) Aggregate number of securities to which transaction applies:
	(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4) Proposed maximum aggregate value of transaction:
	(5) Total fee paid:
	Fee paid previously with preliminary materials.
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
	(1) Amount Previously Paid:
	(2) Form, Schedule or Registration Statement No.:
	(3) Filing Party:
	(4) Date Filed:



Shareholder Meeting Notice

1234 5678 9012 345

Important Notice Regarding the Availability of Proxy Materials for the Haemonetics Corporation Annual Meeting of Shareholders to be Held on Tuesday, July 21, 2020

Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the 2020 Annual Meeting of Shareholders of Haemonetics Corporation are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the meeting are on the reverse side. Your vote is important!

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement and 2020 Annual Report to Shareholders are available at:

www.envisionreports.com/HAE



Easy Online Access – View your proxy materials and vote. Step 1: Go to www.envisionreports.com/HAE.

- Step 2: Click on Cast Your Vote or Request Materials.
- **Step 3:** Follow the instructions on the screen to log in.
- Step 4: Make your selections as instructed on each screen for your delivery preferences.
- Step 5: Vote your shares.

When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.



Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the Company's proxy materials, you must request it. Paper copies of the proxy materials will include the form of proxy card. There is no charge to you for requesting a copy. Please make your request for a copy as instructed on the reverse side on or before July 10, 2020 to facilitate timely delivery.



2 N O T

СОҮ

+

039V9B

Shareholder Meeting Notice

The 2020 Annual Meeting of Shareholders of Haemonetics Corporation (the "Company") will be held on Tuesday, July 21, 2020 at 125 Summer Street, Boston MA 02110, at 8:00 A.M. Eastern Time.

Proposals to be voted on at the meeting are listed below along with the Board of Directors' recommendations.

The Board of Directors recommends a vote FOR the election of each director nominee and FOR Proposals 2 and 3.

Proposals to be considered at the meeting:

- 1. To elect the four director nominees named in the proxy statement to one-year terms expiring in 2021;
- 2. To approve, on an advisory basis, the compensation of our named executive officers;
- 3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending April 3, 2021; and
- 4. To transact such other business as may properly come before the meeting.

PLEASE NOTE - THIS IS NOT A PROXY CARD. YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must vote online or request a paper copy of the proxy materials, which will include a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you.

<u>Shareholders of record as of the record date are invited to attend the 2020 Annual Meeting of Shareholders and vote in person. Instructions on attending</u> gaining admission and voting at the meeting can be found in the proxy statement.



Here's how to order a copy of the proxy materials and select delivery preferences:

Current and future delivery requests can be submitted using the options below.

If you request an email copy, you will receive an email with a link to the current meeting materials.

PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

- Internet Go to www.envisionreports.com/HAE. Click Cast Your Vote or Request Materials.
- Phone Call us free of charge at 1-866-641-4276.
- Email Send an email to investorvote@computershare.com with "Proxy Materials Haemonetics Corporation" in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.

To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by July 10, 2020.